Adipose-derived autologous stem cell therapy - Kasiak Research

Drug Profile

Adipose-derived autologous stem cell therapy - Kasiak Research

Alternative Names: ADMSC - Kasiak Research; ADSC - Kasiak Research; REFACELL-CLI

Latest Information Update: 09 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kasiak Research
  • Class Anti-ischaemics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Peripheral arterial occlusive disorders

Most Recent Events

  • 09 Sep 2016 Phase-I/II development is ongoing in India (Kasiak Research pipeline, September 2016)
  • 01 May 2014 Phase-I/II clinical trials in Peripheral arterial occlusive disorders (critical limb ischaemia) in India (IV)
  • 01 May 2014 Phase-I/II clinical trials in Peripheral arterial occlusive disorders (critical limb ischaemia) in India (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top